Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Alpha Cognition’s ZUNVEYL for Alzheimer’s treatment
The approval of the asset for Alzheimer’s disease was based on comprehensive chemistry, manufacturing, and controls information. Credit: Colin Behrens from Pixabay.
The approval of the asset for Alzheimer’s disease was based on comprehensive chemistry, manufacturing, and controls information. Credit: Colin Behrens from Pixabay.